BPC-157 / TB-500 Blend is strictly for laboratory research and is commonly employed in the following investigational areas:

Endothelial Function and Angiogenesis

Research utilizes this blend to study the differentiation and proliferation of endothelial cells. Studies focus on measuring the expression of angiogenic factors and tube formation capacity, particularly in models involving induced pluripotent stem cells (iPSCs) derived from diabetic patients, where reparative potency is often compromised.

Tissue Repair and Wound Healing Dynamics

In vitro and in vivo models employ BPC-157 to characterize the “angiomodulatory” effect on granulation tissue. Investigators quantify the rate of defect closure and the tensile strength of tissues, examining how the peptide influences the nitric oxide system to modulate inflammatory infiltrates and collagen deposition.

Cytoskeletal Organization and Cell Migration

The TB-500 component is utilized to investigate actin sequestration. Researchers measure the ratio of F-actin to G-actin in motile cells to determine how upregulation of Thymosin Beta-4 influences cytoskeletal reorganization, a critical step in cellular migration and wound re-epithelialization.

Pathway / Mechanistic Context

The primary mechanistic context for this blend in research settings involves the dual modulation of vascular signaling and cytoskeletal plasticity.

• NO System Interaction: BPC-157 is investigated for its ability to interact with the nitric oxide (NO) pathway, potentially balancing NO release to prevent endothelial damage while stimulating vessel formation.
• Actin Sequestration: TB-500 acts by binding to monomeric G-actin, preventing its polymerization into F-actin filaments. This “buffering” mechanism is critical for maintaining a pool of actin monomers available for rapid polymerization during cell migration.
• Vascular Endothelial Growth Factor (VEGF) Axis: Both peptides are studied for their downstream effects on VEGF expression, serving as chemical probes to upregulate vascular repair signaling cascades in ischemic cell models.

Preclinical Research Summary

Published preclinical literature documents investigations of BPC-157 and Thymosin Beta-4 across experimental models for pathway characterization and endpoint measurement:

• Diabetic Endothelial Cells: Research indicates that Thymosin Beta-4 treatment can significantly improve the reparative potency of endothelial cells differentiated from patient-derived iPSCs, characterized by enhanced tube formation and migration assays.
• Wound Healing Models: Extensive studies on BPC-157 highlight its role in accelerating the healing of complex injuries, including fistulas and muscle/tendon defects. Data suggests it exerts a stabilizing effect on the gastric mucosa and promotes granulation tissue formation via NO-dependent pathways.
• Ischemic Tissue Models: In experimental ischemia, data indicates these peptides may preserve tissue viability. Endpoints measured include the reduction of oxidative stress markers and the preservation of mitochondrial function in cells subjected to hypoxic stress.

Form & Analytical Testing

This material is produced via solid-phase peptide synthesis (SPPS) and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm the presence and molecular weight of both peptide components.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the $\ge99\%$ purity standard required for reproducible research data.

Storage & Handling

Stable at room temperature for up to 90 days. For long-term storage, keep at -20C (-4F) or colder.

Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4C (39F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Su, L., Kong, X., Loo, S., et al. (2022). Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. Stem Cell Research & Therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-x
• Seiwerth, S., Milavic, M., Vukojevic, J., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.